Search results
Results From The WOW.Com Content Network
In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. [2] In 2023, the company’s seat in Forbes Global 2000 was 89.
2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur. 2008: Sanofi Pasteur acquires Acambis plc, a biotech company.
CEO, Sanofi. Term. September 2019-. Predecessor. Olivier Brandicourt. Children. 3. Paul Hudson (born 14 October 1967) [2] is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales. [3]
By Ludwig Burger (Reuters) -Sanofi stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer ...
Ken Alltucker, USA TODAY. September 25, 2024 at 5:16 AM. The top of executive of Novo Nordisk told a Senate panel Tuesday it was a "difficult choice" to discontinue the long-acting insulin Levemir ...
Intel’s layoffs, announced Aug. 1, will result in some 15,000 employees losing their jobs. They will arise out of a "comprehensive reduction in spending" that the tech giant said it was pursuing ...
Bayer AG (English: / ˈbaɪ.ər /, commonly pronounced / ˈbeɪər /; [3] German: [ˈbaɪɐ]) is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include: pharmaceuticals, consumer ...
Hoechst AG. Hoechst AG (German pronunciation: [ˈhøːçst]) was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.